---
document_datetime: 2023-09-21 17:40:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/daptomycin-hospira-epar-all-authorised-presentations_en.pdf
document_name: daptomycin-hospira-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9673662
conversion_datetime: 2025-12-20 01:05:13.927138
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number        | Invented name      | Strength   | Pharmaceutical Form                        | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|--------------------|------------|--------------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/17/1175/001 | Daptomycin Hospira | 350 mg     | Powder for solution for injection/infusion | Intravenous use           | vial (glass)          | 350 mg (50 mg/ml)         | 1 vial      |
| EU/1/17/1175/002 | Daptomycin Hospira | 350 mg     | Powder for solution for injection/infusion | Intravenous use           | vial (glass)          | 350 mg (50 mg/ml)         | 5 vials     |
| EU/1/17/1175/003 | Daptomycin Hospira | 500 mg     | Powder for solution for injection/infusion | Intravenous use           | vial (glass)          | 500 mg (50 mg/ml)         | 1 vial      |
| EU/1/17/1175/004 | Daptomycin Hospira | 500 mg     | Powder for solution for injection/infusion | Intravenous use           | vial (glass)          | 500 mg (50 mg/ml)         | 5 vials     |